ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Promising Results of Ketamine Therapy for Depression, PTSD, and Suicidal Ideation Unveiled

Honolulu, HI (Newsworthy.ai) Saturday Dec 23, 2023 @ 7:00 AM Eastern —

Ketamine, a dissociative anesthetic drug initially used for general anesthesia, has emerged as a breakthrough therapy for major depression, post-traumatic stress disorder (PTSD), and suicidal ideation. Recent findings demonstrate that subanesthetic doses of ketamine effectively create a dissociative effect, disconnecting individuals from their negative thoughts, memories, actions, and identity. By dissociating old neuronal connections and facilitating the formation of new, healthy connections in the brain, ketamine presents a promising treatment option for those facing mental health challenges.

Renowned expert and Dr. John Carter explains, "Ketamine works by blocking the 'burst mode' of the lateral habenula, a crucial brain region responsible for suppressing dopamine production after traumatic experiences or ongoing disappointments. By interrupting this 'burst mode,' ketamine swiftly reestablishes dopamine production, leading individuals to experience a profound sense of relief, joy, and gratitude."

Notably, ketamine also plays a pivotal role in dismantling old patterns of thinking in the brain, allowing neurons to reconnect and enabling access to positive thoughts and emotions. This unique mechanism has shown remarkable potential in mitigating the symptoms associated with depression, PTSD, and suicidal ideation.

The therapy is not without its temporary side effects, which may include drowsiness, double vision, confusion, nausea, vomiting, dizziness, and feelings of unease. However, these effects typically subside once the immediate impact of ketamine fades.

Endorsed by leading medical professionals in the field, ketamine therapy continues to yield encouraging outcomes for individuals battling mental health conditions. Its ability to dissociate old neuronal connections, increase dopamine production, and promote the formation of new connections in the brain sets the stage for a future revolution in mental healthcare.

Dr. Sarah Adams, a passionate advocate for ketamine therapy, relays her excitement, stating, "The promising results we have observed thus far have given us renewed hope in revolutionizing the approach to treating depression, PTSD, and suicidal ideation. Our focus now is to ensure wider access to this transformative therapy, empowering individuals to regain control over their mental well-being."

With an ever-growing body of evidence showcasing the therapeutic potential of ketamine, healthcare professionals are optimistic about the impact it will have on the lives of those suffering from depression, PTSD, and suicidal ideation. As further research and advancements pave the way for a brighter future, the possibilities for improved mental health outcomes are infinite.

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform.™

The reference URL for this press release is located here Promising Results of Ketamine Therapy for Depression, PTSD, and Suicidal Ideation Unveiled.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.